Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

New molecules show promise against 2 common bacteria species

Researchers have synthesized two new molecules that are able to kill Staphylococcus aureus and Pseudomonas aeruginosa — two species of bacteria that commonly cause lung infections in people with cystic fibrosis (CF). These new molecules, known as synthetic nano-engineered antimicrobial polymers or SNAPs, showed synergistic bacteria-killing effects when combined with…

Barriers seen in accessing specialty care for CF patients: Study

For people with cystic fibrosis (CF), key barriers to getting specialty care include concerns about addiction and affordability, according to a new survey of clinicians. In fact, more than one-third of respondents cited difficulties for CF patients in accessing specialists and issues with insurance and treatment costs. “In this…

Inhaled TAVT-135 shows promise as treatment for all CF types

TAVT-135, an inhaled treatment candidate being developed for people with cystic fibrosis (CF) regardless of their underlying mutation type, was found to help normalize mucus production in a cell model of the disease. According to researchers from Tavanta Therapeutics, the treatment’s developer, the findings of their in vitro…